logo
Nationwide Deodorant Recall Update as FDA Sets Risk Level

Nationwide Deodorant Recall Update as FDA Sets Risk Level

Newsweek2 days ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A major recall of popular deodorants sold nationwide has been issued the second-highest risk classification by the U.S. Food and Drug Administration (FDA).
The recall of three Power Stick deodorants, affecting more than 67,000 products sold across the United States, was voluntary issued by Pennsylvania-based maker A.P. Deauville on July 10. FDA inspectors classified the recall a Class II on July 31.
The deodorants sold at retailers, including Dollar Tree and Amazon, include: Power Stick for Her Roll-On Antiperspirant Deodorant (Powder Fresh), Power Stick Invisible Protection Roll-On Antiperspirant Deodorant (Spring Fresh), and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant (Original).
Newsweek contacted the company for comment on July 17.
Why It Matters
The recall signaled that the recalled Power Stick products were linked to violations of Current Good Manufacturing Practice (CGMP) requirements, which are intended to ensure drug products are produced under quality systems that assure identity, strength, quality and purity.
A recall is designated Class II status, the second highest of three, in situations where use "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA says.
A.P. Deauville is also a manufacturer of shampoos, conditioners, lotion, body washes and facial wipes.
In 2005, the company's Power Stick product also had a $50,000 settlement with the California Air Resources Board based on accusations that products contained volatile organic compounds beyond the state limit.
What To Know
The recall covered the three antiperspirants with the following lot numbers:
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh, 1.8 oz/ 53 mL UPC Code 815195019313—(21,265 cases)
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL UPC Code 815195018194—(22,482 Cases)
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/53 mL UPC Code 815195018224—(23,467 Cases)
Consumers are urged to top using the products and follow retailer or manufacturer guidance for returns or disposal.
The FDA identified "CGMP deviations" as the reason for the recall but did not specify which regulations were not met.
What People Are Saying
Manufacturer A.P. Deauville, per its website: "Our antiperspirant/deo sticks and shower products are manufactured in our FDA regulated factory. We could save money 'outsourcing' or not caring enough to make it ourselves, but we CHOOSE to own our factory and make our product. With those savings, we can have the best quality and ensure you can afford our great products."
What Happens Next?
The FDA's enforcement report listed the recalls as ongoing.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...

Yahoo

time24 minutes ago

  • Yahoo

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...

Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Inovio Pharmaceuticals Inc (NASDAQ:INO) is on track to submit its BLA for INO 3,107 in the second half of 2025, with the goal of file acceptance by year-end. The company has completed the design verification testing of its Selecttra 5 PSP device, a key milestone for regulatory progress. INO 3,107 has been granted breakthrough therapy designation by the FDA, allowing for a rolling submission of the BLA. Clinical data from INO 3,107 has been published in reputable journals, supporting its potential as a preferred treatment for RRP. Inovio Pharmaceuticals Inc (NASDAQ:INO) has significantly reduced its operating expenses by 31% year-over-year, demonstrating fiscal responsibility. Negative Points Inovio Pharmaceuticals Inc (NASDAQ:INO) experienced a decrease in cash equivalents and short-term investments, from $94.1 million at the end of 2024 to $47.5 million by mid-2025. The company anticipates an operational net cash burn of approximately $22 million for the third quarter of 2025. There is uncertainty regarding the potential need for an advisory committee meeting for the BLA submission, which could impact timelines. The company faces competition from other treatments in the RRP space, which could affect market share and enrollment in confirmatory trials. Inovio Pharmaceuticals Inc (NASDAQ:INO) has not provided specific guidance on the size of its commercial organization, which may impact its ability to effectively launch INO 3,107. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with INO. Q: Are you anticipating having an advisory committee meeting for the BLA submission of INO 3,107? A: Dr. Mike Sumner, Chief Medical Officer, stated that based on interactions with the FDA, there has been no indication that an advisory committee meeting will be necessary. The overall risk-benefit data presented does not suggest a requirement for such a meeting, although the final decision rests with the agency. Q: How does the upcoming regulatory decision for a competitor affect Inovio's launch plans for INO 3,107? A: Dr. Jackie Shea, President and CEO, highlighted significant differences between Inovio's program and the competitor's, including trial design and technology. Inovio's focus is on a placebo-controlled confirmatory trial, and the differences in technology and trial design suggest distinct paths for each product. Q: Was there any delay in the DV testing for the Selecttra 5 PSP device, and how does it impact the BLA submission timeline? A: Dr. Jackie Shea confirmed that while the DV testing involved multiple external vendors and was complex, the overall timeline for the BLA submission remains on track for the second half of the year, with file acceptance expected by year-end. Q: What is the strategy for a redosing approach for INO 3,107 based on recent data? A: Dr. Mike Sumner explained that Inovio plans to implement a redosing strategy, likely involving annual dosing, to enhance the clinical effect and maintain the reduction in surgeries for RRP patients. This approach leverages the strengths of their DNA medicine platform. Q: How does Inovio plan to address potential enrollment challenges for the confirmatory trial if a competitor's product is approved? A: Dr. Mike Sumner noted that the trial is designed to recruit 100 patients across 20 sites in the U.S., and despite potential market competition, there remains a sizable population of patients who may not have immediate access to the competitor's product due to insurance coverage and other factors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030

Yahoo

time31 minutes ago

  • Yahoo

Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030

"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease." BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?- Target type, drug, molecule type, and region. Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market. What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio

MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025
MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025

Business Upturn

time7 hours ago

  • Business Upturn

MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025

Salt Lake City, Aug. 12, 2025 (GLOBE NEWSWIRE) — Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Joint comfort and flexibility are vital for maintaining an active, independent lifestyle — whether it's enjoying daily walks, engaging in sports, or simply moving through the day without stiffness. The conversation around joint health is shifting toward preventative, natural options that align with long-term wellness goals in 2025. MobilityMD has emerged as part of this dialogue, offering a joint support formula built on a foundation of purity, ingredient transparency, and thoughtful formulation. While it avoids overpromising results, the supplement positions itself within the growing category of wellness products designed to complement healthy movement and an active lifestyle. Discover how MobilityMD's carefully selected ingredients are shaping the conversation around joint wellness in 2025. SECTION 1: WHY INTEREST IN 'THE SECRET, PURE INGREDIENT TO SUPPORT HEALTHY JOINTS' IS SURGING IN 2025 Joint health has become a central focus for people of all ages in 2025 — from active adults looking to preserve mobility to those seeking extra support for daily comfort. This growing attention is reflected in online search trends, with Google reporting increases in queries like 'natural joint support,' 'supplements for flexibility,' and 'best ingredients for mobility.' The public is no longer just looking for quick fixes; instead, there is heightened curiosity around long-term strategies that integrate into a balanced, healthy lifestyle. Part of this shift comes from the broader wellness movement, where consumers prioritize transparency, clean sourcing, and minimal additives in the products they choose. Social media platforms, wellness podcasts, and fitness forums are filled with discussions comparing ingredient profiles, sharing personal experiences, and evaluating which formulas fit into individual health routines. MobilityMD has entered this conversation not by making sweeping claims, but by highlighting its focus on purity and thoughtful formulation. This aligns with the expectations of today's wellness-conscious consumers, who often seek products designed to complement an active lifestyle without relying on unnecessary fillers or synthetic additives. SECTION 2: MOBILITYMD'S INGREDIENT-FIRST RESPONSE TO THESE TRENDS MobilityMD was developed with a clear focus on sourcing and formulation choices that align with the modern consumer's expectations for clean, purposeful supplementation. Rather than relying on heavily processed or synthetic compounds, the formula incorporates naturally derived ingredients that have been historically discussed for their association with mobility and joint comfort. Each component is chosen with the intent to complement an active lifestyle while avoiding unnecessary additives that do not contribute to the product's purpose. The ingredient selection process emphasizes purity and transparency. This includes providing clear information about sourcing, composition, and function so that consumers can make informed choices about what they put into their bodies. The formulation also considers how different ingredients work together, aiming for a balanced profile that fits into a variety of health routines — from daily wellness habits to more targeted mobility-focused regimens. Importantly, MobilityMD avoids making direct medical claims. Instead, it positions itself as part of a broader wellness strategy, one that supports consumers in pursuing movement-friendly lifestyles while staying mindful of ingredient integrity. Discover how MobilityMD's ingredient transparency reflects the growing demand for cleaner, more purposeful joint support supplements. SECTION 3: INGREDIENT SPOTLIGHT – WHAT'S INSIDE THE FORMULA The foundation of MobilityMD lies in a carefully curated selection of naturally derived ingredients, each frequently discussed in wellness circles for their historical associations with joint comfort and mobility. While the product avoids making direct health claims, it draws on a blend that reflects both tradition and modern supplement formulation trends. Key components often include botanical extracts that have been explored for their potential to support overall wellness, minerals that play a role in maintaining balanced body functions, and naturally occurring compounds that have been studied for their relevance to healthy aging. Each ingredient is chosen with attention to purity, potency, and its ability to integrate seamlessly into a daily health regimen. MobilityMD also emphasizes the importance of what's left out of the formula. There are no unnecessary fillers, artificial colors, or synthetic preservatives — a choice that resonates with consumers who are mindful of every element they consume. This focus on clean composition positions the supplement within the growing category of wellness products designed for individuals who prioritize ingredient integrity as much as potential functional benefits. SECTION 4: WHAT REDDIT, PODCASTS & TIKTOK CREATORS ARE SAYING Conversations about joint health supplements have expanded well beyond traditional advertising channels in 2025. On Reddit, wellness and fitness communities are filled with discussions about ingredient quality, transparency, and the importance of long-term consistency in supplementation. Users frequently share their experiences with products that align with clean-label trends, and MobilityMD has been mentioned in threads that focus on naturally derived joint support options. Podcasts in the health and wellness space often highlight how consumers are becoming more discerning about supplement choices. Guests on these shows frequently emphasize reading ingredient labels, understanding sourcing, and looking for products that complement an active lifestyle. MobilityMD's ingredient-focused approach aligns with these ongoing discussions, making it a relevant part of broader wellness dialogues. On TikTok, creators in the fitness, yoga, and lifestyle categories are producing short-form content around joint-friendly routines, mobility exercises, and supplement habits that fit into a balanced regimen. While these creators don't make specific claims about results, they often showcase how clean-label supplements can be integrated alongside movement practices to support overall wellness. Learn why MobilityMD is appearing in more conversations about clean, transparent joint support in 2025. SECTION 5: WHO MIGHT BE DRAWN TO THIS TYPE OF SUPPLEMENTATION IN 2025 MobilityMD appeals to a wide range of individuals who prioritize maintaining joint comfort and flexibility as part of their overall wellness goals. Active adults, including those who enjoy walking, hiking, yoga, or recreational sports, may be drawn to the idea of a supplement that aligns with their lifestyle without unnecessary additives. Professionals who spend long hours sitting or standing may also find the clean-label approach appealing, as they look for ways to support movement and ease in daily routines. Similarly, older adults seeking to remain active and independent often look for supplements with a transparent ingredient list that avoids synthetic fillers or artificial preservatives. The eco-conscious and health-conscious crowd is another natural audience for MobilityMD. For these individuals, supplement choice is about more than potential functional benefits — it's about knowing that the formula is built on pure, purposeful components. This aligns with the broader wellness movement of 2025, where consumers increasingly value products that support their personal health goals while also reflecting their ethical and environmental values. SECTION 6: EMERGING WELLNESS & PERFORMANCE INNOVATION – 2025 MARKET REFLECTIONS The wellness and supplement market in 2025 reflects a distinct shift toward ingredient transparency, clean-label formulations, and products that fit seamlessly into long-term health routines. Consumers are increasingly skeptical of overpromising claims and are instead prioritizing supplements that are clear about their composition and intended role in a balanced lifestyle. This has created a strong market for products like MobilityMD, which position themselves as part of a broader wellness toolkit rather than a one-step solution. This trend is driven in part by the rise of self-education in health and nutrition. With more information available online than ever before, people are researching ingredients, comparing labels, and making purchasing decisions based on both scientific discussion and personal values. Social media platforms, wellness blogs, and community forums all contribute to this heightened awareness, creating a consumer base that demands higher standards from supplement brands. Within this environment, joint health remains a high-priority category. As active lifestyles, desk-based work, and healthy aging all intersect, the demand for products that align with everyday mobility needs continues to grow. MobilityMD's focus on purity and purposeful formulation allows it to stand out in a competitive market where consumers are looking for supplements that are as trustworthy as they are functional. Discover why MobilityMD is part of the new wave of clean, ingredient-first wellness products in 2025. SECTION 7: THE PUBLIC DEBATE AROUND JOINT HEALTH SUPPLEMENTS – SIGNALS, SKEPTICISM, AND SATURATION The conversation around joint health supplements in 2025 is both active and divided. Supporters often point to the importance of staying proactive with mobility support, highlighting the role of clean, naturally derived ingredients in long-term wellness routines. They value brands that offer transparency and avoid unnecessary additives, seeing these products as part of a broader strategy to maintain active, comfortable movement. Skeptics, however, question whether supplements are necessary for everyone and emphasize the need for realistic expectations. They often stress that lifestyle habits — such as regular movement, balanced nutrition, and proper hydration — form the foundation of joint health, with supplementation serving as a complement rather than a replacement. Neutral observers see the market as one experiencing rapid expansion, but also increased scrutiny. With many brands competing for attention, consumers are becoming more selective, favoring companies that provide clear ingredient information and maintain a consistent focus on product integrity. For products like MobilityMD, standing out means continuing to align with the values of informed, wellness-conscious buyers while avoiding overreaching claims. SECTION 8: ABOUT MOBILITYMD MobilityMD was created with a clear mission — to offer a joint support supplement that prioritizes purity, ingredient transparency, and alignment with modern wellness values. The brand focuses on sourcing naturally derived components that have been historically discussed in wellness communities for their association with mobility and comfort, while avoiding unnecessary additives or synthetic fillers. Every aspect of the product, from formulation to packaging, reflects a commitment to integrity. MobilityMD positions itself not as a quick-fix solution, but as part of a balanced lifestyle that may include movement practices, mindful nutrition, and regular self-care. By maintaining a clear, educational approach to its ingredients and purpose, the brand builds trust with consumers seeking a supplement that fits seamlessly into their long-term wellness routines. In a supplement landscape crowded with exaggerated promises, MobilityMD stands out for its straightforward, ingredient-first philosophy — offering a choice for those who value both product quality and transparency. See how MobilityMD's ingredient-focused approach is resonating with today's wellness-conscious consumers. SECTION 9: CONTACT MobilityMD – Clean, Ingredient-First Joint Support – Clean, Ingredient-First Joint Support Email: [email protected] Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store